Bod Australia Ltd crosses a major milestone in developing cannabis …

Bod Australia Ltd (ASX:BDA) has formulated a proprietary, sublingual cannabis wafer in association with its partner, specialty pharmaceutical company iX Biopharma (SGX:42C).

The manufacture of the required cannabis wafers for clinical trials is set to commence in the coming weeks, with phase I clinical trials to commence shortly thereafter.

Bod chief executive officer Jo Patterson said: “Having finalised the formulation of Medicabilis in WaferiX form we have another major milestone for the company as it tracks towards the commencement of its phase I clinical trial program.”

READ: Bod Australia gains access to more than 2,000 pharmacies through API deal, shares up 26%

The sublingual cannabis wafer is a unique combination of Bod’s proprietary ECs315 cannabis extract and iX Biopharma’s ‘WaferiX’ technology.

The formulated product, containing Bod’s proprietary cannabis extract, which has been freeze dried into a sublingual wafer, can be placed under the patient’s tongue.

The wafer dissolves rapidly

... read more at: